JPMorgan Chase & Co. Purchases 285,726 Shares of Cryoport, Inc. (NASDAQ:CYRX)

JPMorgan Chase & Co. boosted its position in Cryoport, Inc. (NASDAQ:CYRX) by 1,464.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 305,237 shares of the company’s stock after purchasing an additional 285,726 shares during the period. JPMorgan Chase & Co.’s holdings in Cryoport were worth $2,475,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. AXA S.A. lifted its stake in shares of Cryoport by 274.2% in the 2nd quarter. AXA S.A. now owns 873,217 shares of the company’s stock worth $6,034,000 after purchasing an additional 639,855 shares during the period. Bullseye Asset Management LLC boosted its stake in shares of Cryoport by 58.7% during the 3rd quarter. Bullseye Asset Management LLC now owns 214,264 shares of the company’s stock worth $1,737,000 after acquiring an additional 79,244 shares during the last quarter. Federated Hermes Inc. bought a new stake in shares of Cryoport during the 2nd quarter valued at $774,000. Point72 Asset Management L.P. purchased a new stake in shares of Cryoport in the 3rd quarter worth $3,405,000. Finally, Barclays PLC raised its holdings in Cryoport by 272.9% in the 3rd quarter. Barclays PLC now owns 81,417 shares of the company’s stock worth $660,000 after purchasing an additional 59,582 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Jerrell Shelton sold 50,000 shares of the business’s stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $6.51, for a total value of $325,500.00. Following the sale, the chief executive officer now directly owns 731,897 shares in the company, valued at approximately $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ramkumar Mandalam sold 7,369 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $7.46, for a total value of $54,972.74. Following the transaction, the director now owns 59,497 shares of the company’s stock, valued at $443,847.62. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,869 shares of company stock worth $735,673. 10.10% of the stock is owned by insiders.

Cryoport Trading Up 0.1 %

CYRX stock opened at $7.50 on Tuesday. The company has a market capitalization of $370.73 million, a price-to-earnings ratio of -2.22 and a beta of 1.58. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. Cryoport, Inc. has a 1-year low of $5.32 and a 1-year high of $20.10. The business has a 50 day simple moving average of $7.67 and a two-hundred day simple moving average of $7.88.

Wall Street Analyst Weigh In

Several research firms have issued reports on CYRX. UBS Group boosted their price target on Cryoport from $7.00 to $9.00 and gave the company a “neutral” rating in a report on Friday, October 18th. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 target price for the company. Roth Mkm lowered their price target on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, November 8th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Cryoport in a research note on Friday. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Cryoport currently has a consensus rating of “Moderate Buy” and an average target price of $12.29.

Cryoport Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.